Equities research analysts at StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
NASDAQ XXII opened at $0.11 on Friday. The stock has a market cap of $870,660.00, a price-to-earnings ratio of 0.00 and a beta of 1.39. 22nd Century Group has a 12 month low of $0.09 and a 12 month high of $8.81. The company’s 50 day moving average is $0.31 and its two-hundred day moving average is $0.83.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The firm had revenue of $7.95 million for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Institutional Investors Weigh In On 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
See Also
- Five stocks we like better than 22nd Century Group
- ETF Screener: Uses and Step-by-Step Guide
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What Are Dividends? Buy the Best Dividend Stocks
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Choose Top Rated Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.